Literature DB >> 19020718

Expression of Glut-1 is a prognostic marker for oral squamous cell carcinoma patients.

A W Eckert1, M H W Lautner, H Taubert, J Schubert, U Bilkenroth.   

Abstract

Oral squamous cell carcinoma (OSCC) is among the tenth most common human cancers worldwide with evidence of an increase in incidence rate and mortality. Despite advances in treatment modalities, the prognosis of this cancer is still very poor and has not changed over the past two decades. This study is based on samples collected from 42 patients with a primary OSCC. Immunohistochemical staining for Glut-1 was carried out and compared with the clinicopathological data. Thirty-two patients showed in their tumors a weak or undetectable Glut-1 expression, whereas in tumors of 10 patients a moderate to strong Glut-1 expression was detected. In multivariate Cox's regression hazard analysis, patients whose tumors had a moderate to strong Glut-1 expression possessed a 4.9-fold increased risk of tumor-related death compared to the other patients. Our results suggest that Glut-1 expression is an independent prognostic marker for routine assessment of OSCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020718

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  17 in total

Review 1.  FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma.

Authors:  Désirée Deandreis; Sophie Leboulleux; Caroline Caramella; Martin Schlumberger; Eric Baudin
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

2.  HIF-1α and GLUT-1 Expression in Atypical Endometrial Hyperplasia, Type I and II Endometrial Carcinoma: A Potential Role in Pathogenesis.

Authors:  Dalia Rifaat Al-Sharaky; Asmaa Gaber Abdou; Moshira Mohammed Abdel Wahed; Hend Abdou Kassem
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 3.  Correlation of expression of hypoxia-related proteins with prognosis in oral squamous cell carcinoma patients.

Authors:  A W Eckert; M Kappler; J Schubert; H Taubert
Journal:  Oral Maxillofac Surg       Date:  2012-05-17

4.  Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary.

Authors:  Ja Seung Koo; Haeryoung Kim
Journal:  Tumour Biol       Date:  2011-05-20

5.  Expression and significance of hypoxia-inducible factor-1α and glucose transporter-1 in laryngeal carcinoma.

Authors:  Xiao-Hong Wu; Su-Ping Chen; Jian-Ying Mao; Xue-Xian Ji; Hong-Tian Yao; Shui-Hong Zhou
Journal:  Oncol Lett       Date:  2012-09-26       Impact factor: 2.967

6.  Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients.

Authors:  Helge Taubert; Chris Heidenreich; Hans-Jürgen Holzhausen; Antje Schulz; Matthias Bache; Matthias Kappler; Alexander W Eckert; Peter Würl; Ingo Melcher; Kathrin Hauptmann; Steffen Hauptmann; Klaus-Dieter Schaser
Journal:  BMC Cancer       Date:  2010-02-24       Impact factor: 4.430

7.  Hypoxia promotes the invasion and metastasis of laryngeal cancer cells via EMT.

Authors:  Jianhong Zuo; Juan Wen; Mingsheng Lei; Meiling Wen; Sai Li; Xiu Lv; Zhaoyang Luo; Gebo Wen
Journal:  Med Oncol       Date:  2016-01-09       Impact factor: 3.064

8.  Glut-1 as a prognostic biomarker in oral squamous cell carcinoma.

Authors:  Jyotsna M Harshani; Sivaranjani Yeluri; Venkateswara Rao Guttikonda
Journal:  J Oral Maxillofac Pathol       Date:  2014 Sep-Dec

9.  Metabolic phenotypes in primary unknown metastatic carcinoma.

Authors:  Hye Min Kim; Do Hee Kim; Woo Hee Jung; Ja Seung Koo
Journal:  J Transl Med       Date:  2014-01-06       Impact factor: 5.531

10.  The human cell surfaceome of breast tumors.

Authors:  Júlia Pinheiro Chagas da Cunha; Pedro Alexandre Favoretto Galante; Jorge Estefano Santana de Souza; Martin Pieprzyk; Dirce Maria Carraro; Lloyd J Old; Anamaria Aranha Camargo; Sandro José de Souza
Journal:  Biomed Res Int       Date:  2013-09-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.